Lb Pharmaceuticals Inc. (LBRX) intrinsic value & 10-year financials
Lb Pharmaceuticals Inc. (LBRX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $36.74
- Market cap
- $295.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 69.4%
- Free cash flow (FY2025)
- -$35.3M
LBRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$25.2M | -$3.13 | -$35.3M | — | 83.5% |
| FY2024 | — | -$63.1M | -$8.01 | -$53.8M | — | 55.2% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LB PHARMACEUTICALS INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LB PHARMACEUTICALS INC has earned high returns on invested capital, averaging 69.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
LB PHARMACEUTICALS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
LB PHARMACEUTICALS INC is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.